| First Author | Arriaga JM | Year | 2020 |
| Journal | Nat Cancer | Volume | 1 |
| Issue | 11 | Pages | 1082-1096 |
| PubMed ID | 34085047 | Mgi Jnum | J:309100 |
| Mgi Id | MGI:6755613 | Doi | 10.1038/s43018-020-00125-0 |
| Citation | Arriaga JM, et al. (2020) A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. Nat Cancer 1(11):1082-1096 |
| abstractText | Understanding the intricacies of lethal prostate cancer poses specific challenges due to difficulties in accurate modeling of metastasis in vivo. Here we show that NPK (EYFP) mice (for Nkx3.1 (CreERT2/+) ; Pten (flox/flox) ; Kras (LSL-G12D/+) ; R26R-CAG-(LSL-EYFP/+)) develop prostate cancer with a high penetrance of metastasis to bone, thereby enabling detection and tracking of bone metastasis in vivo and ex vivo. Transcriptomic and whole-exome analyses of bone metastasis from these mice revealed distinct molecular profiles conserved between human and mouse and specific patterns of subclonal branching from the primary tumor. Integrating bulk and single-cell transcriptomic data from mouse and human datasets with functional studies in vivo unravels a unique MYC/RAS co-activation signature associated with prostate cancer metastasis. Finally, we identify a gene signature with prognostic value for time to metastasis and predictive of treatment response in human patients undergoing androgen receptor therapy across clinical cohorts, thus uncovering conserved mechanisms of metastasis with potential translational significance. |
